Prenetics Global Limited (Incorporated in the Cayman Islands with limited liability) Condensed Consolidated Financial Statements For the six months ended

Prenetics Global Limited

(Incorporated in the Cayman Islands with limited liability)

Condensed Consolidated Financial Statements

For the six months ended June 30, 2025

Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the six months ended June 30, 2025

(All amounts in thousands of U.S. dollars ( $ ), except for share and per share data)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Condensed Consolidated Statement of Financial Position

(All amounts in thousands of U.S. dollars ( $ ))

Condensed Consolidated Statement of Financial Position - continued

(All amounts in thousands of U.S. dollars ( $ ))

The accompanying notes are an integral part of these condensed consolidated financial statements.

Condensed Consolidated Statement of Changes in Equity

For the six months ended June 30, 2025

(All amounts in thousands of U.S. dollars ( $ ))

Condensed Consolidated Statement of Cash Flows

For the six months ended June 30, 2025

(All amounts in thousands of U.S. dollars ( $ ))

Condensed Consolidated Statements of Cash Flows - continued

For the six months ended June 30, 2025

(All amounts in thousands of U.S. dollars ( $ ))

Notes to the condensed consolidated financial statements

For the six months ended June 30, 2025

(All amounts in thousands of U.S. dollars ( $ ), except for share, and otherwise stated)

1 Basis of preparation

The condensed consolidated financial statements of Prenetics Global Limited and its subsidiaries (collectively, the "Group") for the six months ended 30 June 2025 have been prepared in accordance with International Accounting Standard 34 ( IAS 34 ) Interim Financial Reporting issued by the International Accounting Standards Board ( IASB ). The Group has prepared the consolidated financial statements on the basis that it will continue to operate as a going concern.

The condensed consolidated financial statements do no include all the information and disclosures required in the annual consolidated financial statements, and should be read in conjunction with the Group's annual consolidated financial statements as at December 31, 2024.

Restatement relating to the ACT Genomics disposition

On 18 June 2025, the Prenetics Global Limited (the Company ) announced that the Company had entered into a definitive agreement to divest its 70% equity interest in ACT Genomics Holdings Company Limited ("ACT Genomics"). The disposal was completed on October 1, 2025, on which date control of ACT Genomics passed to the acquirer. The comparative figures in the condensed consolidated financial statements have been restated to re-present the results of ACT Genomics as a discontinued operation.

2 Accounting policies

The condensed consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments, which are measured at revalued amounts or fair values, as appropriate.

Other than additional change in accounting policies resulting from application of amendments to IFRS Accounting Standards issued by the IASB and application of certain accounting policies which became relevant to the Group in the current interim period, the accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended June 30, 2025 are the same as those presented in the Group's annual consolidated financial statements for the year ended December 31, 2024.

Application of amendments to IFRS Accounting Standards

In the current interim period, the Group has applied the following amendments to IFRS Accounting Standards issued by the IASB, for the first time, which are mandatorily effective for the Group's annual period beginning on June 30, 2025 for the preparation of the Group's condensed consolidated financial statements

The application of the amendments to IFRS Accounting Standards issued by the IASB in the current interim period has had no material impact on the Group's financial positions and performance for the current and prior periods and or on the disclosures set out in these condensed consolidated financial statements

The Group derives its revenue from contracts with customers for the transfer of goods and services both at a point in time and over time, across the following major product lines. The disclosure of revenue by product line is consistent with the revenue information that is disclosed for each reportable segment under IFRS 8 Operating Segments ( IFRS 8 ) (see note 4).

Disaggregation of revenue

Revenue expected to be recognized in the future arising from contracts with customers in existence at the report date

As at June 30, 2025 and December 31, 2024, the amount of service fee income allocated to the remaining performance obligations under the Group's existing non-refundable contracts were $6,623 and $6,475, respectively. The Group will recognize the expected revenue in the future when the performance obligations are fulfilled, which may be after one year from the end of the reporting period. Such amount does not include any variable consideration.

4 Segment information

Products and services from which reportable segments derive their revenues

The Group manages its businesses by divisions, which are organized based on the nature of the products and services offered. For management purposes, the Group is divided into two reportable segments under IFRS 8, which align with how the Group's Chief Operating Decision Maker (the CODM ) reviews financial performance and allocates resources.

The Group operates its businesses in three reportable segments (i) Prevention segment, and (ii) Consumer Health segment. The Group's reportable segments are as follows

1.Prevention being the design and sale of genetic testing and

2.Consumer Health being provision of consumer health products, including health and wellness products, and fulfillment and distribution services of sports nutrition products.

4 Segment information (continued)

The following is an analysis of the Group's revenue and gross profit from continuing operations by reportable segments. Performance is measured based on gross profit from continuing operations, as included in the internal management reports that are reviewed by the CODM

Unallocated direct costs represent the unallocated depreciation and amortization related to property, plant and equipment and intangible assets commonly used across segments, and certain staff costs commonly worked across segments.

Segment revenue from continuing operations reported above represents revenue generated from external customers. There were no inter-segment sales for the six months ended June 30, 2025 and 2024.

No analysis of the Group's assets and liabilities by reportable segment is disclosed as they are not regularly provided to the CODM for review.

Segment gross profit represents the gross profit earned by each segment without allocation of certain direct costs associated with depreciation and amortization and certain staff costs commonly used across segments. This is the measure reported to the CODM for the purposes of resource allocation and performance assessment.

The following is the reconciliation of the reportable segments' gross profit from continuing operation to the loss before taxation for the six months ended June 30, 2025 and 2024.

Revenues from major products and services

The Group's revenues from continuing operations from its major products and services are disclosed in note 3.

4 Segment information (continued)

Geographical information

Information about the Group's revenue from continuing operations from external customers is presented based on the location of the customers. Information about the Group's non-current assets is presented based on the geographical location of the assets.

Continuing operations

Non-current assets exclude those relating to discontinued operation, financial assets at fair value through profit or loss and deferred tax assets.

Information about major customers

No single customer from continuing operations contributed 10% or more to the Group's revenue from continuing operations during the six months ended June 30, 2025 and 2024.

5 Other income and other net gain

Note During the six months ended 30 June 2025, the Group obtained government subsidies of $79 under the Research Talent Hub program of Innovation and Technology Fund, administered by the Innovation and Technology Commission of The Government of Hong Kong Special Administrative Region. The Research Talent Hub aims to provide funding support for companies undertaking research and development projects funded by the Innovation and Technology Fund to engage research talent to conduct research and development work.

The provision for Hong Kong Profits Tax is calculated by applying the estimated annual effective tax rate of 16.5% for the six months ended June 30, 2025 and 2024, except for one subsidiary of the Group which is a qualifying corporation under the two-tiered Profits Tax rate regime.

The U.S. federal tax rate is 21% for the six months ended June 30, 2025 and 2024.

Taxation for other overseas subsidiaries and branch is charged at the appropriate current rates of taxation ruling in the relevant countries.

7 Loss for the period

Loss for the period has been arrived at after charging

(a)Other finance costs

7 Loss for the period - continued

8 Discontinued operation

On June 18, 2025, the Company entered into a sale and purchase agreement to dispose of its entire interests in ACT Genomics and its subsidiaries to customary closing conditions.

The assets and liabilities attributable to ACT Genomics, which are expected to be transferred to the acquirer upon completion within twelve months, have been classified as a disposal group held for sale in accordance with IFRS 5 Non-current Assets Held for Sale and Discontinued Operations ( IFRS 5 ) and are presented separately in the condensed consolidated statement of financial position. In accordance with IFRS 5, the comparative figures for the six months ended June 30, 2024 have been restated to present the results of ACT Genomics as a discontinued operation.

The net proceeds of disposal are expected to exceed the net carrying amount of the disposal group and accordingly, no impairment loss has been recognized.

The major classes of assets and liabilities of ACT Genomics classified as held for sale are as follows

Cumulative amount of $30,965 relating to the disposal group classified as held for sale has been recognized in other comprehensive income and included in equity.

8 Discontinued operation - continued

Results of discontinued operation

The loss from discontinued operation of $3,037 and $4,109 was attributable to the equity shareholders of the Company and $942 and $906 was attributable to the non-controlling interests for the six months ended June 30, 2025 and 2024, respectively. The total comprehensive expense from continuing operations of $19,375 and $15,951 was attributable entirely to the equity shareholders of the Company and $1 and $2 was attributable to the non-controlling interests for the six months ended June 30, 2025 and 2024, respectively.